MEK1 promotes YAP and their interaction is critical for tumorigenesis in liver cancer

FEBS Letters

Volumn 587, Issue 24, 2013, Pages 3921-3927

  Li, Lanlan ^a,b   Wang, Jiayi ^a   Zhang, Yue ^a   Zhang, Yan ^a   Ma, Lifang ^a   Weng, Wenhao ^a   Qiao, Yongxia ^c   Xiao, Weifan ^a   Wang, Hongmei ^a   Yu, Wenjun ^a   Pan, Qiuhui ^a   He, Yunyan ^b   Sun, Fenyong ^a  

^a TONGJI UNIVERSITY   (China)

^b ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

BTRC; Cell signaling; ERK1 2; HCC; Hippo pathway

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; BETA TRANSDUCIN REPEAT CONTAINING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PROTEIN KINASE YES;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CANCER; LIVER CARCINOGENESIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TARGET CELL;

EID: 84888642428     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1016/j.febslet.2013.10.042     Document Type: Article

References (25)

1. P.A. Farazi, and R.A. DePinho Hepatocellular carcinoma pathogenesis from genes to environment Nat. Rev. Cancer 6 2006 674 687
2. Q. Zeng, and W. Hong The emerging role of the hippo pathway in cell contact inhibition, organ size control, and cancer development in mammals Cancer Cell 13 2008 188 192
3. M.Z. Xu, T.J. Yao, N.P. Lee, I.O. Ng, Y.T. Chan, L. Zender, S.W. Lowe, R.T. Poon, and J.M. Luk Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma Cancer 115 2009 4576 4585
4. M.Z. Xu, S.W. Chan, A.M. Liu, K.F. Wong, S.T. Fan, J. Chen, R.T. Poon, L. Zender, S.W. Lowe, W. Hong, and J.M. Luk AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma Oncogene 30 2011 1229 1240
5. R. Urtasun, M.U. Latasa, M.I. Demartis, S. Balzani, S. Goñi, O. Garcia-Irigoyen, M. Elizalde, M. Azcona, R.M. Pascale, F. Feo, P. Bioulac-Sage, C. Balabaud, J. Muntané, J. Prieto, C. Berasain, and M.A. Avila Connective tissue growth factor autocriny in human hepatocellular carcinoma: oncogenic role and regulation by epidermal growth factor receptor/yes-associated protein-mediated activation Hepatology 54 2011 2149 2158
6. D.F. Tschaharganeh, X. Chen, P. Latzko, M. Malz, M.M. Gaida, K. Felix, S. Ladu, S. Singer, F. Pinna, N. Gretz, C. Sticht, M.L. Tomasi, S. Delogu, M. Evert, B. Fan, S. Ribback, L. Jiang, S. Brozzetti, F. Bergmann, F. Dombrowski, P. Schirmacher, D.F. Calvisi, and K. Breuhahn Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma Gastroenterology 144 2013 1530 1542
7. E.M. Morin-Kensicki, B.N. Boone, M. Howell, J.R. Stonebraker, J. Teed, J.G. Alb, T.R. Magnuson, W. O'Neal, and S.L. Milgram Defects in yolk sac vasculogenesis, chorioallantoic fusion, and embryonic axis elongation in mice with targeted disruption of Yap65 Mol. Cell. Biol. 26 2006 77 87
8. J. Wang, L. Ma, W. Weng, Y. Qiao, Y. Zhang, J. He, H. Wang, W. Xiao, L. Li, Q. Chu, Q. Pan, Y. Yu, and F. Sun Mutual interaction between YAP and CREB promotes tumorigenesis in liver cancer Hepatology 58 2013 1011 1020
9. T. Van Biesen, B.E. Hawes, D.K. Luttrell, K.M. Krueger, K. Touhara, E. Porfiri, M. Sakaue, L.M. Luttrell, and R.J. Lefkowitz Receptor-tyrosine-kinase and GBγ mediated MAPK kinase activation by a common signaling pathway Nature 376 1995 781 784
10. P. Lenormand, G. Ages, C. Sardet, G. L'Allemain, S. Meloche, and J. Pouysségur MAP kinases: activation, subcellular localization and role in the control of cell activation Adv. Second Messenger Phosphoprotein Res. 28 1993 237 244
11. S.J. Mansouer, W.T. Mathen, A.S. Harmann, J.M. Candia, S. Rong, K. Fukasawa, G.F. Vande Woude, and N.G. Ahn Transformation of mammalian cells by constitutively active MAP kinase kinase Science 265 1994 966 970
12. C.A. Wiesenauer, M.T. Yip-Schneider, Y. Wang, and C.M. Schmidt Multiple anticancer effects of blocking MEK-ERK signaling in hepatocellular carcinoma J. Am. Coll. Surg. 198 2004 410 421
13. K. Fukudo, K. Tsuchihara, M. Hijikata, S. Nishiguchi, T. Kuroki, and K. Shimotohno Hepatitis C virus core protein enhances the activation of the transcription factor, Elk1, in response to mitogenic stimuli Hepatology 33 2001 159 165
14. J. Hayashi, H. Aoki, and K. Kajino Hepatitis C virus core protein activates the MAPK/ERK cascade synergistically with the tumor promoter TPA, but not with epidermal growth factor or transforming growth factor Hepatology 32 2000 958 961
15. T. Zhang, J. Zhang, X. You, Q. Liu, Y. Du, Y. Gao, C. Shan, G. Kong, Y. Wang, X. Yang, L. Ye, and X. Zhang Hepatitis B virus X protein modulates oncogene Yes-associated protein by CREB to promote growth of hepatoma cells Hepatology 56 2012 2051 2059
16. B. Zhao, X. Ye, J. Yu, L. Li, W. Li, S. Li, J. Yu, J.D. Lin, C.Y. Wang, A.M. Chinnaiyan, Z.C. Lai, and K.L. Guan TEAD mediates YAP-dependent gene induction and growth control Genes Dev. 22 2008 1962 1971
17. C.L. Creasy, D.M. Ambrose, and J. Chernoff The Ste20-like protein kinase, Mst1, dimerizes and contains an inhibitory domain J. Biol. Chem. 271 1996 21049 21053
18. Y. Yung, Z. Yao, D.M. Aebersold, T. Hanoch, and R. Seger Altered regulation of ERK1b by MEK1 and PTP-SL and modified Elk1 phosphorylation by ERK1b are caused by abrogation of the regulatory C-terminal sequence of ERKs J. Biol. Chem. 276 2001 35280 35289
19. E.J. Chung, M.E. Urick, N. Kurshan, W. Shield, H. Asano, P.D. Smith, B.S. Scroggins, J. Burkeen, and D.E. Citrin MEK1/2 inhibition enhances the radiosensitivity of cancer cells by downregulating survival and growth signals mediated by EGFR ligands Int. J. Oncol. 42 2013 2028 2036
20. S.V. Holt, A. Logié, R. Odedra, A. Heier, S.P. Heaton, D. Alferez, B.R. Davies, R.W. Wilkinson, and P.D. Smith The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models Br. J. Cancer 106 2012 858 866
21. B. Zhao, L. Li, K. Tumaneng, C.Y. Wang, and K.L. Guan A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP) Genes Dev. 24 2010 72 85
22. L. Gailhouste, F. Ezan, A. Bessard, C. Frémin, J. Rageul, S. Langouët, and G. Baffet RNAi-mediated MEK1 knock-down prevents ERK1/2 activation and abolishes human hepatocarcinoma growth in vitro and in vivo Int. J. Cancer 126 2010 1367 1377
23. J. Wang, J.S. Park, Y. Wei, M. Rajurkar, J.L. Cotton, Q. Fan, B.C. Lewis, H. Ji, and J. Mao TRIB2 acts downstream of Wnt/TCF in liver cancer cells to regulate YAP and C/EBPα function Mol. Cell 51 2013 211 225
24. W. Cui, N. Xiao, H. Xiao, H. Zhou, M. Yu, J. Gu, and X. Li β-TrCP-mediated IRAK1 degradation releases TAK1-TRAF6 from the membrane to the cytosol for TAK1-dependent NF-κB activation Mol. Cell. Biol. 32 2012 3990 4000
25. N. Popov, C. Schülein, L.A. Jaenicke, and M. Eilers Ubiquitylation of the amino terminus of Myc by SCF(β-TrCP) antagonizes SCF(Fbw7)-mediated turnover Nat. Cell Biol. 12 2010 973 981